These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 17944907)
21. A study of impurities in intermediates and 3,4-methylenedioxymethamphetamine (MDMA) samples produced via reductive amination routes. Gimeno P; Besacier F; Bottex M; Dujourdy L; Chaudron-Thozet H Forensic Sci Int; 2005 Dec; 155(2-3):141-57. PubMed ID: 16226151 [TBL] [Abstract][Full Text] [Related]
22. The impurity characteristics of methamphetamine synthesized by Emde and Nagai method. Ko BJ; Suh S; Suh YJ; In MK; Kim SH Forensic Sci Int; 2007 Aug; 170(2-3):142-7. PubMed ID: 17630239 [TBL] [Abstract][Full Text] [Related]
23. Variability in content and dissolution profiles of MDMA tablets collected in the UK between 2001 and 2018 - A potential risk to users? Couchman L; Frinculescu A; Sobreira C; Shine T; Ramsey J; Hecht M; Kipper K; Holt D; Johnston A Drug Test Anal; 2019 Aug; 11(8):1172-1182. PubMed ID: 31009168 [TBL] [Abstract][Full Text] [Related]
24. Impact of Pharmaceutical Impurities in Ecstasy Tablets: Gas Chromatography-Mass Spectrometry Study. Jalali A; Hatamie A; Saferpour T; Khajeamiri A; Safa T; Buazar F Iran J Pharm Res; 2016; 15(1):221-9. PubMed ID: 27610162 [TBL] [Abstract][Full Text] [Related]
25. Characteristics and trends of 3,4-methylenedioxymethamphetamine (MDMA) tablets found in Taiwan from 2002 to February 2005. Teng SF; Wu SC; Liu C; Li JH; Chien CS Forensic Sci Int; 2006 Sep; 161(2-3):202-8. PubMed ID: 16842946 [TBL] [Abstract][Full Text] [Related]
26. Supported liquid-liquid extraction of the active ingredient (3,4-methylenedioxymethylamphetamine) from ecstasy tablets for isotopic analysis. de Korompay A; Hill JC; Carter JF; NicDaeid N; Sleeman R J Chromatogr A; 2008 Jan; 1178(1-2):1-8. PubMed ID: 18070626 [TBL] [Abstract][Full Text] [Related]
27. Basic and neutral route specific impurities in MDMA prepared by different synthesis methods. Comparison of impurity profiles. Swist M; Wilamowski J; Parczewski A Forensic Sci Int; 2005 Dec; 155(2-3):100-11. PubMed ID: 16226147 [TBL] [Abstract][Full Text] [Related]
28. N-cyanomethyl-N-methyl-1-(3',4'-methylenedioxyphenyl)-2-propylamine: an MDMA manufacturing by-product. Salouros H; Collins M; Tarrant G; George AV J Forensic Sci; 2008 Sep; 53(5):1083-91. PubMed ID: 18637869 [TBL] [Abstract][Full Text] [Related]
29. Availability of target odor compounds from seized ecstasy tablets for canine detection. Macias MS; Furton KG J Forensic Sci; 2011 Nov; 56(6):1594-600. PubMed ID: 21827456 [TBL] [Abstract][Full Text] [Related]
30. A review of impurity profiling and synthetic route of manufacture of methylamphetamine, 3,4-methylenedioxymethylamphetamine, amphetamine, dimethylamphetamine and p-methoxyamphetamine. Stojanovska N; Fu S; Tahtouh M; Kelly T; Beavis A; Kirkbride KP Forensic Sci Int; 2013 Jan; 224(1-3):8-26. PubMed ID: 23182870 [TBL] [Abstract][Full Text] [Related]
31. Profiling of volatile impurities in tetramethylenedisulfotetramine (TETS) for synthetic-route determination. Fraga CG; Wahl JH; Núñez SP Forensic Sci Int; 2011 Jul; 210(1-3):164-9. PubMed ID: 21444165 [TBL] [Abstract][Full Text] [Related]
32. Chemical composition of Ecstasy tablets seized in Poland between 2005 and 2020. Byrska B; Stanaszek R Forensic Toxicol; 2024 Jul; ():. PubMed ID: 39017813 [TBL] [Abstract][Full Text] [Related]
33. Rapid drug-screening of clandestine tablets by MALDI-TOF mass spectrometry. Su AK; Liu JT; Lin CH Talanta; 2005 Oct; 67(4):718-24. PubMed ID: 18970230 [TBL] [Abstract][Full Text] [Related]
34. Profiling of ecstasy tablets seized in iran. Khajeamiri AR; Kobarfard F; Ahmadkhaniha R; Mostashari G Iran J Pharm Res; 2011; 10(2):211-20. PubMed ID: 24250345 [TBL] [Abstract][Full Text] [Related]
35. The use of organic and inorganic impurities found in MDMA police seizures in a drug intelligence perspective. Morelato M; Beavis A; Tahtouh M; Ribaux O; Kirkbride P; Roux C Sci Justice; 2014 Jan; 54(1):32-41. PubMed ID: 24438775 [TBL] [Abstract][Full Text] [Related]
36. NIR analysis of cellulose and lactose--application to ecstasy tablet analysis. Baer I; Gurny R; Margot P Forensic Sci Int; 2007 Apr; 167(2-3):234-41. PubMed ID: 16860953 [TBL] [Abstract][Full Text] [Related]
37. Chemical profile of meta-chlorophenylpiperazine (m-CPP) in ecstasy tablets by easy ambient sonic-spray ionization, X-ray fluorescence, ion mobility mass spectrometry and NMR. Romão W; Lalli PM; Franco MF; Sanvido G; Schwab NV; Lanaro R; Costa JL; Sabino BD; Bueno MI; de Sa GF; Daroda RJ; de Souza V; Eberlin MN Anal Bioanal Chem; 2011 Jul; 400(9):3053-64. PubMed ID: 21475947 [TBL] [Abstract][Full Text] [Related]
38. Recovery of integrated and surface trace DNA from illicit drug tablets. Griffin A; Kirkbride KP; Henry J; Painter B; Linacre A Forensic Sci Int Genet; 2022 Nov; 61():102772. PubMed ID: 36099863 [TBL] [Abstract][Full Text] [Related]
39. Sugar and fatty acid analysis in ecstasy tablets. Baer I; Margot P Forensic Sci Int; 2007 Apr; 167(2-3):229-33. PubMed ID: 16889919 [TBL] [Abstract][Full Text] [Related]
40. Application of two-dimensional gas chromatography combined with pixel-based chemometric processing for the chemical profiling of illicit drug samples. Gröger T; Schäffer M; Pütz M; Ahrens B; Drew K; Eschner M; Zimmermann R J Chromatogr A; 2008 Jul; 1200(1):8-16. PubMed ID: 18539290 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]